Targeted therapies and immunotherapies have an earlier role to play in the management of melanoma, according to interim findings from two international studies in predominantly stage III resected disease. The findings, presented this week at the European Society for Medical Oncology (ESMO) Annual Congress, suggest patients should not have to wait for recurrence before accessing ...
Evidence to move therapy earlier in melanoma
By Mardi Chapman
13 Sep 2017